- 64 次围观
产品图片
货号/SKU
NR-52481
货号/规格
EA
库存与交货期
3-8周
人民币价格
14000
试剂海关审批
A/B级风险物质只能直接使用人购买并持有实验室有效资质，其它询客服确认
国外采购
支持/部分限制一年内购买数量
厂牌
BEI Resources(ATCC)
产品基础信息
生物安全等级建议分类：美国、1
产品描述信息
NR-52481?? Monoclonal Anti-SARS Coronavirus Recombinant Human Antibody, Clone CR3022 (produced in HEK293 Cells)(Monoclonal Antibodies)|SARS Coronavirus|Monoclonal Anti-SARS Coronavirus Recombinant Human Antibody, Clone CR3022 (produced in HEK293 Cells)| -20°C or colder |F Krammer, V Chromikova, GA ArunkumarAcknowledgment for publications should read “The following reagent was produced under HHSN272201400008C and obtained through BEI Resources, NIAID, NIH: Monoclonal Anti-SARS Coronavirus Recombinant Human Antibody, Clone CR3022 (produced in HEK293 Cells), NR-52481.”|Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment.
Predicted Antibody Class: IgG1κ
Human monoclonal antibody CR3022 was identified via an immune phage display library, constructed from lymphocytes of a convalescent severe acute respiratory syndrome coronavirus (SARS-CoV) patient. CR3022 is a neutralizing antibody that targets the receptor binding domain (RBD) of the spike (S) glycoprotein of SARS-CoV. NR-52481 features the CR3022 epitope introduced into a human IgG1κ molecule, and was produced in human embryonic kidney (HEK293) cells using a transient expression system and purified by protein G chromatography. The epitope of CR3022 does not overlap with the ACE2-binding site within the S glycoprotein RBD from severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2). CR3022 targets a highly conserved epitope that enables cross-reactive binding between SARS-CoV-2 and SARS-CoV. The CR3022 epitope has been co-crystallized with the SARS-CoV-2 S protein receptor binding domain (RBD) (6W41, 6YM0 and 6YLA) at a range of 2.4 to 4.4 ?, the S1 protein domain (6YOR) at 3.3 ?, the S protein RBD and neutralizing antibody CC12.1 (6XC3) at 2.7 ?, the S protein RBD and neutralizing antibody CC12.3 (6XC7) at 2.9 ?, and the S protein RBD and nanobody H11-D4 (6Z2M and 6YZ7) at 3.3 and 4.3 ?, respectively.
NR-52481 is specific to the S glycoprotein and has been shown to neutralize SARS-CoV. CR3022 recognizes the full-length SARS-CoV-2 S1 protein fused to a human IgG1 Fc domain (S1-Fc) under reducing and non-reducing conditions, as well as a hexa-histidine-tagged S glycoprotein RBD alone, in western blot analysis. CR3022 binds potently to SARS-CoV-2 RBD as determined by ELISA and western blot.
Applications include western blot analysis and ELISA.
Each vial of NR-52481 contains approximately 100 ?L of purified monoclonal antibody in phosphate buffered saline (PBS).
Predicted Antibody Class: IgG1κ
Human monoclonal antibody CR3022 was identified via an immune phage display library, constructed from lymphocytes of a convalescent severe acute respiratory syndrome coronavirus (SARS-CoV) patient. CR3022 is a neutralizing antibody that targets the receptor binding domain (RBD) of the spike (S) glycoprotein of SARS-CoV. NR-52481 features the CR3022 epitope introduced into a human IgG1κ molecule, and was produced in human embryonic kidney (HEK293) cells using a transient expression system and purified by protein G chromatography. The epitope of CR3022 does not overlap with the ACE2-binding site within the S glycoprotein RBD from severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2). CR3022 targets a highly conserved epitope that enables cross-reactive binding between SARS-CoV-2 and SARS-CoV. The CR3022 epitope has been co-crystallized with the SARS-CoV-2 S protein receptor binding domain (RBD) (6W41, 6YM0 and 6YLA) at a range of 2.4 to 4.4 ?, the S1 protein domain (6YOR) at 3.3 ?, the S protein RBD and neutralizing antibody CC12.1 (6XC3) at 2.7 ?, the S protein RBD and neutralizing antibody CC12.3 (6XC7) at 2.9 ?, and the S protein RBD and nanobody H11-D4 (6Z2M and 6YZ7) at 3.3 and 4.3 ?, respectively.
NR-52481 is specific to the S glycoprotein and has been shown to neutralize SARS-CoV. CR3022 recognizes the full-length SARS-CoV-2 S1 protein fused to a human IgG1 Fc domain (S1-Fc) under reducing and non-reducing conditions, as well as a hexa-histidine-tagged S glycoprotein RBD alone, in western blot analysis. CR3022 binds potently to SARS-CoV-2 RBD as determined by ELISA and western blot.
Applications include western blot analysis and ELISA.
Each vial of NR-52481 contains approximately 100 ?L of purified monoclonal antibody in phosphate buffered saline (PBS).
主要内容
此项目的每个订单数量限制为1.此商品每年可订购两次.此限制的订单将在发货前发送到NIAID批准.
预测抗体类：IgG1κ
通过免疫噬菌体展示文库鉴定人单克隆抗体CR3022，由促进的严重急性呼吸综合征冠状病毒（SARS-COV）患者的淋巴细胞构成. CR3022是靶向SARS-COV的穗糖蛋白的受体结合结构域（RBD）的中和抗体. NR-52481具有引入人IgG1κ分子的CR3022表位，并使用瞬时表达系统在人胚胎肾（HEK293）细胞中产生并通过蛋白G色谱法纯化. CR3022的表位与来自严重急性呼吸综合征相关的冠状病毒2（SARS-COV-2）的S糖蛋白RBD中的ACE2结合位点不重叠. CR3022靶向高度保守的表位，使得SARS-COV-2和SARS-COV之间的交叉反应结合能够. CR3022表位与SARS-COV-2 S蛋白受体结合结构域（RBD）（ 6w41， 6ym0 和 6yla ）在2.4至4.4?的范围内，S1蛋白域（ 6yor ）在3.3?，S蛋白质RBD和中和抗体CC12.1（ 6xc3 ）在2.7?，S蛋白RBD和中和抗体Cc12.3（ 6xc7 ）在2.9?，以及S蛋白质RBD和纳米曲面H11-D4（6z2m 和 6yz7 ）分别为3.3和4.3?.
NR-52481特异于S糖蛋白，已被证明以中和SARS-COV. CR3022识别到在减少和非还原条件下与人IgG1 Fc结构域（S1-Fc）融合的全长SARS-COV-2 S1蛋白，以及单独的六征组氨酸标记的糖蛋白RBD，在Western印迹中分析. CR3022均致力于SARS-COV-2 RBD，如ELISA和Western印迹所确定的.
应用包括Western印迹分析和ELISA.
NR-52481的每个小瓶中含有约100μl的磷酸盐缓冲的纯化的单克隆抗体
盐水（PBS）.
厂牌介绍
BEI Resources 由美国国家过敏和传染病研究所 ( NIAID )成立，旨在为研究 A、B 和 C 类优先病原体、新兴传染病病原体、非病原微生物和其他相关微生物材料提供试剂、工具和信息到研究界。BEI Resources 获取、验证和生产科学家进行基础研究和开发改进的诊断测试、疫苗和疗法所需的试剂。通过将这些功能集中在 BEI Resources 中，可以监控科学界对这些材料的访问和使用，并确保试剂的质量控制。
除了为传染病界提供材料外，BEI Resources 还鼓励和支持研究人员和机构的材料存放。使用 BEI Resources存放材料对研究人员和研究社区有许多优势，包括安全存储、社区访问和分发；同时保护存款人的知识产权。只要有需要，BEI 资源库将作为研究人员的资源进行维护。您在 BEI Resources 的存款是一项有助于未来研究的长期投资。
BEI Resources 自 2003 年起由美国典型培养物保藏中心 (ATCC) 根据合同管理。2016 年 5 月， ATCC获得了一份为期七年的继续管理 BEI Resources的合同。合同范围已扩大到更全面的研究目录材料，包括由其他政府支持的研究项目存放的材料，将提供给生物防御和新兴传染病科学界。真菌、寄生虫、载体和其他相关材料已添加到现有的细菌、病毒和毒素试剂中，涵盖 NIAID A、B 和 C 类优先病原体和 NIAID 指定的新发传染病病原体和生物。
品牌标识
可能感兴趣的内容
2024-01-21
2022-06-17
2022-03-31
2022-04-01
2022-04-01
2022-06-17
2022-04-01
2022-04-01
2021-12-02
2021-12-13
2024-06-14
2024-01-21
2022-04-01
2021-12-13
2021-12-21
2019-05-08